UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.019

Sortiert nach

Crizotinib Can Overcome Acquired Resistance to CH5424802: Is Amplification of the MET Gene a Key Factor?

Journal of thoracic oncology, 2014-03, Vol.9 (3), p.e27-e28

2014

Link zum Volltext

Verfügbarkeit prüfen

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.195-199

2020

Link zum Volltext

Verfügbarkeit prüfen

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

European journal of cancer (1990), 2019-05, Vol.113, p.78-86

2019

Link zum Volltext

Verfügbarkeit prüfen

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

The lancet respiratory medicine, 2017-01, Vol.5 (1), p.42-50

2017

Link zum Volltext

Verfügbarkeit prüfen

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

The lancet oncology, 2013-06, Vol.14 (7), p.590-598

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-07, Vol.38 (19), p.2187-2196

2020

Link zum Volltext

Verfügbarkeit prüfen

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

Cancer science, 2015-09, Vol.106 (9), p.1202-1211

2015

Link zum Volltext

Verfügbarkeit prüfen

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer

Current Treatment Options in Oncology, 2015-12, Vol.16 (12), p.56, Article 56

2015

Link zum Volltext

Verfügbarkeit prüfen

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

International journal of clinical oncology, 2019-07, Vol.24 (7), p.731-770

2019

Link zum Volltext

Verfügbarkeit prüfen

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study

Pediatrics international, 2022-01, Vol.64 (1), p.e15106-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Lung cancer (Amsterdam, Netherlands), 2018-03, Vol.117, p.14-19

2018

Link zum Volltext

Verfügbarkeit prüfen

KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer

Cancer science, 2019-03, Vol.110 (3), p.1012-1020

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Cancer science, 2018-09, Vol.109 (9), p.2863-2872

2018

Link zum Volltext

Verfügbarkeit prüfen

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

Cancer science, 2021-04, Vol.112 (4), p.1556-1566

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105

Journal of clinical oncology, 2010-08, Vol.28 (23), p.3739-3745

2010

Link zum Volltext

Verfügbarkeit prüfen

Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell Lung Cancer

Annals of surgical oncology, 2021-06, Vol.28 (6), p.3046-3054

2021

Link zum Volltext

Verfügbarkeit prüfen

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

OncoTargets and therapy, 2018-01, Vol.11, p.5093-5101

2018

Link zum Volltext

Verfügbarkeit prüfen

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP

Journal of clinical oncology, 2017-05, Vol.35 (14), p.1515-1521

2017

Link zum Volltext

Verfügbarkeit prüfen

Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy

Lung cancer (Amsterdam, Netherlands), 2019-02, Vol.128, p.26-32

2019

Link zum Volltext

Verfügbarkeit prüfen

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)

PloS one, 2021-10, Vol.16 (10), p.e0258616-e0258616

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.019

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(797)
Mit Volltextzugriff
(975)

Publikationsform

Sprache

Englisch
(895)
Japanisch
(352)
Deutsch
(4)
Koreanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(535)
Life Sciences & Biomedicine
(434)
Humans
(330)
Male
(233)
Oncology
(222)
Female
(208)
Middle Aged
(190)
Aged
(178)
Adult
(150)
Lung Neoplasms - Drug Therapy
(106)
Lung Cancer
(99)
Biological And Medical Sciences
(96)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(88)
Chemotherapy
(82)
Physical Sciences
(80)
Medical Sciences
(78)
Aged, 80 And Over
(77)
Respiratory System
(77)
Lung Neoplasms - Pathology
(73)
Patients
(70)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Crizotinib Can Overcome Acquired Resistance to CH5424802: Is Amplification of the MET Gene a Key Factor?

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105

Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell Lung Cancer

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP

Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)

Suchergebnisse filtern